Jan H M Schellens
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
Dec 12, 2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Dec 12, 2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950.
Nov 20, 2019Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Nov 20, 2019CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950
Jacobs Bart A W, Deenen Maarten J, Joerger Markus, Rosing Hilde, de Vries Niels, Meulendijks Didier, Cats Annemieke, Beijnen Jos H, Schellens Jan H M, Huitema Alwin D R
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharm Res 2019; 36:33.
Jan 7, 2019Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Jan 7, 2019Pharm Res 2019; 36:33
Crombag Marie-Rose B S, Beijnen Jos H, Mathijssen Ron H J, van Erp Nielka P, Dorlo Thomas P C, Schellens Jan H M, Jörger Markus, Wijngaard Sophie, Koolen Stijn L W, de Vries Schultink Aurelia H M, Huitema Alwin D R
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8
Jan 2, 2016Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Jan 2, 2016Cancers (Basel) 2016; 8
Crombag Marie-Rose B S, Jörger Markus, Thürlimann Beat, Schellens Jan H M, Beijnen Jos H, Huitema Alwin D R
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
Sep 1, 2012Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Sep 1, 2012Clin Pharmacokinet 2012; 51:607-17
Jörger Markus, Kraff Stefanie, Huitema Alwin D R, Feiss Gary, Moritz Berta, Schellens Jan H M, Beijnen Jos H, Jaehde Ulrich
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
Feb 1, 2012Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Feb 1, 2012Br J Clin Pharmacol 2012; 73:240-7
Jörger Markus, Ferreri Andrés J M, Krähenbühl Stephan, Schellens Jan H M, Cerny Thomas, Zucca Emanuele, Huitema Alwin D R
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.
Sep 28, 2011Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
Sep 28, 2011Cancer 2011; 118:2466-75
Jörger Markus, Beijnen Jos H, Huitema Alwin D R, Vincent Andrew, Smits Paul H M, Doodeman Valerie D, Bard Martin P L, Haitjema Tjeerd J, Smit Egbert F, Baas Paul, Burgers Sjaak A, Schellens Jan H M
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen W, Burgers J, Vincent A, Schellens J, Beijnen J, Smit E, Jörger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
Jul 6, 2010Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Jul 6, 2010J Clin Oncol 2010; 28:e482-3; author reply e484
Buikhuisen Wieneke A, Burgers Jacobus A, Vincent Andrew D, Schellens Jan H M, Beijnen Jos H, Smit Egbert F, Jörger Markus
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Jörger M, Hollema H, Féty R, Van der Vijgh W, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Boddy A, Calvert H, Jodrell D, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, Sleeboom H, Izquierdo M, Schellens J. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8.
Nov 1, 2007Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Nov 1, 2007Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8
Jörger Markus, Hollema Harry, Féty Régine, Van der Vijgh Wjf J F, Hempel Georg, Chatelut Etienne, Karlsson Mats, Wilkins Justin, Tranchand Brigitte, Schrijvers Ad H G J, Twelves Christian, Beijnen Jos H, Boddy Alan V, Calvert Hilary, Jodrell Duncan I, Huitema Alwin D R, Richel Dick J, Dittrich Christian, Pavlidis Nikolas, Briasoulis Evangelos, Vermorken Jan B, Strocchi Elena, Martoni Andrea, Sorio Roberto, Sleeboom Henk P, Izquierdo Miguel A, Schellens Jan H M
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
Jörger M, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Schellens J, Jodrell D, Izquierdo M, Sleeboom H, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical pharmacokinetics 2007; 46:1051-68.
Jan 1, 2007Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
Jan 1, 2007Clinical pharmacokinetics 2007; 46:1051-68
Jörger Markus, Féty Régine, de Bruijn Ernst, Hempel Georg, Karlsson Mats, Tranchand Brigitte, Schrijvers Ad H G J, Twelves Chris, Beijnen Jos H, Schellens Jan H M, Jodrell Duncan I, Izquierdo Miguel A, Sleeboom Henk P, Huitema Alwin D R, Richel Dick J, Dittrich Christian, Pavlidis Nikolas, Briasoulis Evangelos, Vermorken Jan B, Strocchi Elena, Martoni Andrea, Sorio Roberto, EORTC-PAMM-NDDG
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
Sparidans R, Bosch T, Jörger M, Schellens J, Beijnen J. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53.
Jul 24, 2006Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
Jul 24, 2006Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53
Sparidans Rolf W, Bosch T M, Jörger Markus, Schellens Jan H M, Beijnen Jos H
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors
Jörger M, Huitema A, van den Bongard D, Schellens J, Beijnen J. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7.
Apr 1, 2006Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors
Apr 1, 2006Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7
Jörger Markus, Huitema Alwin D R, van den Bongard Desiree H J G, Schellens Jan H M, Beijnen Jos H